<DOC>
	<DOCNO>NCT01443481</DOCNO>
	<brief_summary>This multi-center , open label study ass pharmacokinetics ( PK ) TKI258 single-dose steady state adult cancer patient either mild , moderate severe hepatic impairment normal hepatic function . Hepatic function study patient categorize normal , mild , moderate severe base upon pre-dose ( Day 1 ) total bilirubin AST/ALT level . Starting dose TKI258 depend total bilirubin ALT/AST level baseline . Patients treat disease progression ( assessed RECIST 1.1 ) , unacceptable toxicity , death discontinuation study treatment reason .</brief_summary>
	<brief_title>Pharmacokinetics ( PK ) TKI258 Cancer Patients With Normal Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm solid tumor , exclude breast cancer , either refractory standard therapy available therapy . 2 . ECOG performance status ( PS ) 0 1 3 . Patients must measurable and/or nonmeasurable lesion ( ) assess Computer Tomography ( CT ) Scan Magnetic Resonance Imaging ( MRI ) per RECIST 1.1 1 . Patients know brain metastasis . 2 . Patients undergone major surgery â‰¤ 4 week prior start study treatment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>hepatic impairment</keyword>
	<keyword>Child-Pugh classification</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>PK</keyword>
	<keyword>RECIST 1.1</keyword>
</DOC>